Osimert 80mg Tablet 30’s

Product Details

Osimert 80mg Tablet also know as Tagrisso  contains the active ingredient Osimertinib, a targeted therapy used to treat non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that works by blocking the activity of the EGFR protein, which can promote the growth and spread of cancer cells. It is effective against cancers that have developed resistance to previous EGFR-targeted treatments and can cross the blood-brain barrier, making it useful for treating metastatic brain tumors.

Uses:

• Treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M mutation-positive cases.
• Effective for managing brain metastases in NSCLC with specific EGFR mutations.

Side Effects:

• Common side effects: diarrhea, rash, dry skin, and changes in nail appearance.
• Serious side effects: interstitial lung disease, heart rhythm disturbances (QT prolongation), and decreased white blood cell count. Contact your healthcare provider immediately if you experience symptoms such as breathing difficulties, chest pain, or persistent cough.

Key Features:

• Contains osimertinib, a third-generation EGFR tyrosine kinase inhibitor.
• Targets specific EGFR mutations in advanced or resistant NSCLC.
• Can cross the blood-brain barrier to treat brain metastases.
• Demonstrates efficacy in slowing disease progression and improving survival in patients with EGFR-mutated NSCLC.

FAQ:

1. How does Osimert 80mg Tablet work?
   Osimert inhibits the EGFR protein, which drives cancer growth in certain lung cancers. By blocking this pathway, it can slow or stop the spread of cancer cells.
2. Who can use Osimert?
   Osimert is prescribed for patients with advanced or metastatic NSCLC harboring specific EGFR mutations, including the T790M mutation, confirmed through genetic testing.
3. What precautions should I take while on Osimert?
   Regular monitoring for lung function, heart health, and blood counts is recommended. Report any new respiratory symptoms, such as cough or shortness of breath, as these could indicate lung-related side effects.

References:

1. AstraZeneca Pharmaceuticals. “Tagrisso (osimertinib) Tablets.” [Accessed on 5 Nov 2024]. Available from: https://medlineplus.gov/druginfo/meds/a616005.html
2. European Medicines Agency (EMA). “Osimertinib Product Information.” [Accessed on 5 Nov 2024]. Available from: https://www.medicines.org.uk/emc/product/7615/smpc